Strategies to genetically engineer T cells for cancer immunotherapy Journal Article


Authors: Spear, T. T.; Nagato, K.; Nishimura, M. I.
Article Title: Strategies to genetically engineer T cells for cancer immunotherapy
Abstract: Immunotherapy is one of the most promising and innovative approaches to treat cancer, viral infections, and other immune-modulated diseases. Adoptive immunotherapy using gene-modified T cells is an exciting and rapidly evolving field. Exploiting knowledge of basic T cell biology and immune cell receptor function has fostered innovative approaches to modify immune cell function. Highly translatable clinical technologies have been developed to redirect T cell specificity by introducing designed receptors. The ability to engineer T cells to manifest desired phenotypes and functions is now a thrilling reality. In this review, we focus on outlining different varieties of genetically engineered T cells, their respective advantages and disadvantages as tools for immunotherapy, and their promise and drawbacks in the clinic.
Journal Title: Cancer immunology, immunotherapy : CII
Volume: 65
Issue: 6
ISSN: 1432-0851; 0340-7004
Publisher: Unknown  
Journal Place: Germany
Date Published: 2016
Start Page: 631
End Page: 649
Language: eng
DOI/URL:
Notes: LR: 20160701; GR: F30 CA180731/CA/NCI NIH HHS/United States; GR: P01 CA154778/CA/NCI NIH HHS/United States; GR: R01 CA090873/CA/NCI NIH HHS/United States; JID: 8605732; OTO: NOTNLM; 2016/01/08 [received]; 2016/04/25 [accepted]; 2016/05/02 [aheadofprint]; ppublish